NCT06831903 Radiotherapy of Head and Neck Cancer With SIB
| NCT ID | NCT06831903 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Wuerzburg University Hospital |
| Condition | Quality of Life (QOL) |
| Study Type | OBSERVATIONAL |
| Enrollment | 750 participants |
| Start Date | 2019-05-21 |
| Primary Completion | 2034-10-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 750 participants in total. It began in 2019-05-21 with a primary completion date of 2034-10-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Title: Simultaneous Integrated Boost in Primary and Adjuvant Therapy of Head and Neck Tumors: Quality Control Registry Prospective Longitudinal Observational Study Short Title: Radiotherapy for Head and Neck Tumors with SIB Objective: To evaluate the efficacy and safety of definitive and adjuvant radio(chemo)therapy with simultaneous integrated boost (SIB) in patients with head and neck cancers. The study aims to assess local and regional control, overall survival, metastasis-free survival, therapy-related toxicities, and quality of life. Study Design: A prospective, longitudinal, non-interventional registry study documenting real-world outcomes and quality measures of therapy applied according to existing clinical guidelines.
Eligibility Criteria
Inclusion Criteria: * Patients aged 18 and older with histologically confirmed malignant head and neck tumors, undergoing definitive or adjuvant radio(chemo)therapy at the University Hospital Würzburg Exclusion Criteria: * missing informed consent * mental or physical disorders leading to inability to understand and/or fill the quationary * judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures
Contact & Investigator
Victor Lewitzki, MD, PhD
PRINCIPAL INVESTIGATOR
University Clinic of Wuerzburg, Department of Radiation Oncology
Frequently Asked Questions
Who can join the NCT06831903 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Quality of Life (QOL). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06831903 currently recruiting?
Yes, NCT06831903 is actively recruiting participants. Contact the research team at lewitzki_v@ukw.de for enrollment information.
Where is the NCT06831903 trial being conducted?
This trial is being conducted at Würzburg, Germany.
Who is sponsoring the NCT06831903 clinical trial?
NCT06831903 is sponsored by Wuerzburg University Hospital. The principal investigator is Victor Lewitzki, MD, PhD at University Clinic of Wuerzburg, Department of Radiation Oncology. The trial plans to enroll 750 participants.